The biological basis of fractionation in radiotherapy

Clinical and Translational Oncology

Volumn 4, Issue 3, 2002, Pages 161-166

  Muriel, Vicente Pedraza ^a  

^a University Hospital   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33846866398     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. O'Dwyer PJ, Johnson SW, Hamilton TC. Cisplatin and its analogues. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer principles & practice of oncology. 5th ed. Philadelphia: Lippincott-Raven; 1997. p. 418-32
2. Rixe O, Ortura W, Alvarez M, et al. Oxaloplatin, tetraplatin, cisplatin and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996;52:1855-65.
3. Mathe G, Kidany Y, Triana K, et al. A phase I trial of Trans-I-diaminocyclohexane oxalato-platinum. Biomed Pharmacother 1986;40:372-6.
4. Extra JM, Espie M, Calvo F, et al. Phase I study of oxaloplatin in patients with advanced cancer. Cancer Pharmacother 1990;25:299-303.
5. Mitchell EP, Lo Russo P, Giococo K, et al. Safely profile of oxaloplatin (single agent or with 5-FU) from the large North American comjpassionate use experience in advanced colorectal cancer. Pro Am Soc Clin Oncol 2000 (Abstrat 1259).
6. Medioni J, Coulon MA, Morete JF, et al. Anaphilaxis after oxaloplatin. Onn Oncol 1999;10:610.
7. Santini D, Tonini A, Salerno A, et al. Idiosyncratic reaction after oxaloplatin infusion. Ann Oncology 2001; 12:131-3.
8. Immunoglobulin E-Initiated immune reactions in (eds) 199. p. 298-312.
9. Muller-Werdam U, Werdam K. Wien Klin Wochenschr 2000;112(4):149-56.